Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis

European Journal of Internal Medicine

Volumn 33, Issue , 2016, Pages 60-66

  Rokkas, T ^a   Portincasa, P ^b  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Cancer; Colon; Diabetes; Meta analysis; Metformin; Polyps

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COLON CANCER; COLON POLYP; COLON TUMOR; DIABETIC PATIENT; DRUG EFFECT; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; COLONIC NEOPLASMS; COLONIC POLYPS; DIABETES MELLITUS, TYPE 2; PATHOLOGY; RISK FACTOR;

COLONIC NEOPLASMS; COLONIC POLYPS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84991255992     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2016.05.027     Document Type: Article

References (74)

1. [1] Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. [2] Anderson, W.F., Umar, A., Brawley, O.W., Colorectal carcinoma in black and white race. Cancer Metastasis Rev 22 (2003), 67–82.
3. [3] Das, D., Arber, N., Jankowski, J.A., Chemoprevention of colorectal cancer. Digestion 76 (2007), 51–67.
4. [4] Citarda, F., Tomaselli, G., Capocaccia, R., et al. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 48 (2001), 812–815.
5. [5] Drazen, J.M., COX-2 inhibitors–a lesson in unexpected problems. N Engl J Med 352 (2005), 1131–1132.
6. [6] Meyskens, F.L. Jr., McLaren, C.E., Pelot, D., et al. Difluoromethylornithine plus sulindac for the prevention of sporadiccolorectal adenomas: a randomized placebo-controlled, double-blindtrial. Cancer Prev Res (Phila) 1 (2008), 32–38.
7. [7] Limburg, P.J., Vierkant, R.A., Fredericksen, Z.S., et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 101 (2006), 1872–1879.
8. [8] Larsson, S.C., Orsini, N., Wolk, A., Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97 (2005), 1679–1687.
9. [9] Frezza, E.E., Wachtel, M.S., Chiriva-Internati, M., Influence of obesity on the risk of developing colon cancer. Gut 55 (2006), 285–291.
10. [10] Bhaskaran, K., Douglas, I., Forbes, H., et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384 (2014), 755–765.
11. [11] Nathan, D.M., Buse, J.B., Davidson, M.B., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52 (2009), 17–30.
12. [12] Cusi, K., DeFronzo, R.A., Metformin: a review of its metabolic effects. Diabetes Rev 6 (1998), 89–131.
13. [13] Papanas, N., Maltezos, E., Mikhailidis, D.P., Metformin: diamonds are forever. Expert Opin Pharmacother 10 (2009), 2395–2397.
14. [14] Nestler, J.E., Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358 (2008), 47–54.
15. [15] Goodwin, P.J., Ligibel, J.A., Stambolic, V., Metformin in breast cancer: time for action. J Clin Oncol 27 (2009), 3271–3273.
16. [16] Li, D., Yeung, S.C., Hassan, M.M., Konopleva, M., Abbruzzese, J.L., Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137 (2009), 482–488.
17. [17] Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S.S., Meier, C.R., Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33 (2010), 1304–1308.
18. [18] DeCensi, A., Puntoni, M., Goodwin, P., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3 (2010), 1451–1461.
19. [19] Zhang, Z.J., Zheng, Z.J., Kan, H., Song, Y., Cui, W., Zhao, G., et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. Diabetes Care 34 (2011), 2323–2328.
20. [20] Noto, H., Goto, A., Tsujimoto, T., Noda, M., Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One, 7, 2012, e33411.
21. [21] Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 111 (2014), 1432–1439.
22. [22] Wu, G.F., Zhang, X.L., Luo, Z.G., Yan, J.J., Pan, S.H., Ying, X.R., et al. Metformin therapy and prostate cancer risk: a meta-analysis of observational studies. Int J Clin Exp Med 8 (2015), 13089–13098.
23. [23] Higgins, J.P.T., Green, S., Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane collaboration., 2011 [Available: http://www.cochrane-handbook.org].
24. [24] Mantel, N., Haenszel, W., Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959), 719–748.
25. [25] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
26. [26] Cochran, W.G., The combination of estimates from different experiments. Biometrics 8 (1954), 101–129.
27. [27] Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
28. [28] Sutton, A.J., Abrams, K.R., Jones, D.R., et al. In: Methods for meta-analysis in medical research. 2000, John Wiley & Sons, Ltd, New York.
29. [29] Higgins, J.P., Thompson, S.G., Deeks, J.J., Measuring inconsistency in meta-analysis. BMJ 327 (2003), 557–560.
30. [30] Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to meta-analysis. New York: John Wiley & Sons Ltd; ….
31. [31] Copas, J.B., Shi, J.Q., A sensitivity analysis for publication bias in systematic reviews. Stat Methods Med Res 10 (2001), 251–265.
32. [32] Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
33. [33] Egger, M., Davey Smith, G., Schneider, M., et al. Bias in meta-analysis detected by a simple graphical test. BMJ 315 (1997), 29–34.
34. [34] Duval, S., Tweedie, R., Trim and fill: a simple funnel plot- based method of testing and in meta-analysis. Biometrics 56 (2000), 455–463.
35. [35] Yang, Y.X., Hennessy, S., Lewis, J.D., Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127 (2004), 1044–1050.
36. [36] Oliveria, S., Koro, C.E., Yood, M.U., Sowell, M., Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr Clin Res Rev 2 (2008), 47–57.
37. [37] Currie, C.J., Poole, C.D., Gale, E.A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 (2009), 1766–1777.
38. [38] Libby, G., Donnelly, L.A., Donnan, P.T., Alessi, D.R., Morris, A.D., Evans, J.M., New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32 (2009), 1620–1625.
39. [39] Home, P.D., Kahn, S.E., Jones, N.P., Noronha, D., Beck-Nielsen, H., Viberti, G., Experience of malignancies with oral glucose-lowering drugs in the randomized controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation Of Glycaemia in Diabetes) clinical trials. Diabetologia 53 (2010), 1838–1845.
40. [40] Lee, M.S., Hsu, C.C., Wahlqvist, M.L., Tsai, H.N., Chang, Y.H., Huang, Y.C., Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer, 11, 2011, 20.
41. [41] Morden, N.E., Liu, S.K., Smith, J., Mackenzie, T.A., Skinner, J., Korc, M., Further exploration of the relationship between insulin glargine and incident cancer. Diabetes Care 34 (2011), 1965–1971.
42. [42] Bodmer, M., Becker, C., Meier, C., Jick, S.S., Meier, C.R., Use of metformin is not associated with a decreased risk of colorectal cancer: a case–control analysis. Cancer Epidemiol Biomarkers Prev 21 (2011), 280–286.
43. [43] Hsieh, M.C., Lee, T.C., Cheng, S.M., Tu, S.T., Yen, M.H., Tseng, C.H., The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res, 2012, 2012, 413782.
44. [44] Ruiter, R., Visser, L.E., Van Herk-Sukel, M., Coebergh, J.W.W., Haak, H.R., Geelhoed-Duijvestijn, P.H., et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives. Diabetes Care 35 (2012), 119–124.
45. [45] Kanadiya, M.K., Gohel, T.D., Sanaka, M.R., Thota, P.N., Shubrook, J.H. Jr., Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complications 5 (2013), 463–466.
46. [46] Smiechowski, B., Azoulay, L., Yin, H., Pollak, M.N., Suissa, S., The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 22 (2013), 1877–1883.
47. [47] Wang, S.Y., Chuang, C.S., Muo, C.H., Tu, S.T., Lin, M.C., Sung, F.C., et al. Metformin and the incidence of cancer in patients with diabetes: a nested case–control study. Diabetes Care 36 (2013), e155–e156.
48. [48] Tsilidis, K.K., Capothanassi, D., Allen, N.E., Rizos, E.C., Lopez, D.S., van Veldhoven, K., et al. Metformin does not affect cancer risk: a cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial. Diabetes Care 37 (2014), 2522–2532.
49. [49] Cho, Y.H., Ko, B.M., Kim, S.H., Myung, Y.S., Cho, J.H., Han, J.P., et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus?. Int Rescuer 12 (2014), 139–145.
50. [50] Chen, Y.C., Kok, V.C., Chien, C.H., Horng, J.T., Tsai, J.J.P., Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator. Ther Clin Risk Manag 11 (2015), 1315–1323.
51. [51] Kim, Y.H., Noh, R., Cho, S.Y., Park, S.J., Jeon, S.M., Shin, H.D., et al. Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes. Int Rescuer 13 (2015), 145–152.
52. [52] Zhang, Z.Z., Zheng, Z.J., Kan, H., Song, Y., Cui, W., Zhao, G., et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. Diabetes Care 34 (2011), 2323–2328.
53. [53] Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G.F.M., Pellegrini, F., Nicolucci, A., et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One, 8, 2013, e71583.
54. [54] Singh, S., Singh, H., Singh, P.P., Murad, H., Limburg, P.J., Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 22 (2013), 2258–2268.
55. [55] Gandini, S., Puntoni, M., Heckman-Stoddard, B.M., Dunn, B.K., Ford, L., DeCensi, A., et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7 (2014), 867–885.
56. [56] Lega, I.C., Shah, P.S., Margel, D., Beyene, J., Rochon, P.A., Lipscombe, L.L., The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev 23 (2014), 1974–1984.
57. [57] Zakikhani, M., Dowling, R.J., Sonenberg, N., Pollak, M.N., The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1 (2008), 369–375.
58. [58] Buzzai, M., Jones, R.G., Amaravadi, R.K., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53- deficient tumor cell growth. Cancer Res 67 (2007), 6745–6752.
59. [59] Algire, C., Amrein, L., Zakikhani, M., Panasci, L., Pollak, M., Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17 (2010), 351–360.
60. [60] Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., et al. Metformin suppresses azoxymethaneinduced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 49 (2010), 662–671.
61. [61] Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99 (2008), 2136–2141.
62. [62] Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res 3 (2010), 1077–1083.
63. [63] Alessi, D.R., Sakamoto, K., Bayascas, J.R., LKB1-dependent signaling pathways. Annu Rev Biochem 75 (2006), 137–163.
64. [64] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., et al. Role of AMP activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001), 1167–1174.
65. [65] Dong, S.M., Kim, K.M., Kim, S.Y., Shin, M.S., Na, E.Y., Lee, S.H., et al. Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers syndrome gene in left-sided colon cancer. Cancer Res 58 (1998), 3787–3790.
66. [66] Park, W.S., Moon, Y.W., Yang, Y.M., Kim, Y.S., Kim, Y.D., Fuller, B.G., et al. Mutations of the STK11 gene in sporadic gastric carcinoma. Int J Oncol 13 (1998), 601–604.
67. [67] Inoki, K., Guan, K.-L., Complexity of the TOR signalling network. Trends Cell Biol 16 (2006), 206–212.
68. [68] Yang, Y.X., Do diabetes drugs modify the risk of pancreatic cancer?. Gastroenterology 137 (2009), 412–415.
69. [69] Sandhu, M.S., Dunger, D.B., Giovannucci, E.L., Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94 (2002), 972–980.
70. [70] LeRoith, D., Baserga, R., Helman, L., Roberts, C.T. Jr., Insulin-like growth factors and cancer. Ann Intern Med 122 (1995), 54–59.
71. [71] Renehan, A.G., Tyson, M., Egger, M., Heller, R.F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 (2008), 569–578.
72. [72] Grenader, T., Goldberg, A., Shavit, L., Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol, 35, 2009, e259.
73. [73] Zhuang, Y., Miskimins, W.K., Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal, 3, 2008, 18.
74. [74] Hirsch, H.A., Iliopoulos, D., Tsichlis, P.N., Struhl, K., Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69 (2009), 7507–7511.